Clinical trials: sponsored by British Columbia Cancer Agency
Prostate Cancer
Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer
This study will offer men with intermediate risk prostate cancer who are suitable for, and interested in, prostate brachytherapy, the opportunity to be randomized between low dose rate (LDR) brachytherapy using permanent…
- Trial name
- NCT02692105
- Testing
- Low dose rate prostate brachytherapy, High Dose Rate prostate brachytherapy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- British Columbia Cancer Agency
Recurrent Prostate Cancer
Partial Prostate Salvage High Dose Rate Brachytherapy
A dose-response relationship for radiation in the management of prostate cancer is well established. Local recurrence of prostate cancer after external beam radiotherapy occurs in at least 40% of patients treated because of…
- Trial name
- SalvageHDR (NCT03246802)
- Testing
- HDR partial prostate brachytherapy
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- British Columbia Cancer Agency
Prostate CA
Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prostate Cancer
Prostate cancer is a common cancer, and a significant cause of cancer death in men. There are many potentially curative treatment options for prostate cancers that have not spread.
- Trial name
- ADAPT-25 (NCT06835725)
- Testing
- Stereotactic Body Radiation Therapy (SBRT)
- Where
- 2 sites in Canada
- Volunteers
- 100 people
- Sponsor
- British Columbia Cancer Agency
Neuroendocrine Tumors, Insulinoma
DOTATOC PET/CT for Imaging NET Patients
Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of special molecules called…
- Conditions
- Neuroendocrine Tumors, Insulinoma, Gastrinoma, Glucagonoma
- Trial name
- NCT03583528
- Testing
- 68Ga-DOTATOC PET/CT, 18F-FDG PET/CT
- Where
- Canada
- Volunteers
- 800 people
- Sponsor
- British Columbia Cancer Agency
Oligometastatic Prostate Cancer
5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)
We will investigate whether ultrahypofractionation using stereotactic ablative radiotherapy (SABR) or brachytherapy is as well-tolerated as moderately hypofractionated external beam radiotherapy (EBRT) for treating the prostate…
- Trial name
- PROMPT (NCT04610372)
- Testing
- Hypofractionated external beam radiotherapy, High dose rate brachytherapy, Permanent seed implant
- Where
- 4 sites in Canada
- Volunteers
- 168 people
- Sponsor
- British Columbia Cancer Agency
Metastatic Tumors
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer
Stereotactic Ablative Radiotherapy (SABR) is a modern RT technique that delivers high doses of radiation to small tumor targets using highly conformal techniques. SABR is non-invasive and delivered on an outpatient basis.
- Trial name
- SABR-COMET-3 (NCT03862911)
- Testing
- palliative radiotherapy, Stereotactic ablative radiotherapy
- Where
- 17 sites in Australia, Canada and 2 more
- Volunteers
- 330 people
- Sponsor
- British Columbia Cancer Agency
Neoplasm Metastasis, Neoplastic Processes
SUPR-3D: Simple Unplanned Palliative Radiotherapy Versus 3D Conformal Radiotherapy for Patients With Bone Metastases
The primary objective is to patient-reported Quality of Life related to complete control of Radiation Induced Nausea and Vomiting (RINV) between standard palliative radiotherapy and VMAT.
- Conditions
- Neoplasm Metastasis, Neoplastic Processes, Neoplasms, Pathologic Processes
- Trial name
- NCT03694015
- Testing
- SUPR, VMAT
- Where
- 5 sites in Canada
- Volunteers
- 160 people
- Sponsor
- British Columbia Cancer Agency
Vulvar Cancer
STRatIfication of Vulvar Squamous Cell Carcinoma by HPV and p53 Status to Guide Excision
Vulvar cancer affects the external genitalia of women. This type of cancer is uncommon, arising mostly in older women and has been neglected in research and clinical trials.
- Trial name
- STRIVE (NCT05576831)
- Testing
- Re-excision
- Where
- Canada
- Volunteers
- 249 people
- Sponsor
- British Columbia Cancer Agency
Early Stage Breast Cancer
Partial Breast Irradiation Using Interstitial Permanent Palladium-103 Seed Implant
Permanent Breast Seed Implant (PBSI) has been demonstrated to be a well accepted and well tolerated form of partial breast radiotherapy.
- Trial name
- PBSI (NCT02297672)
- Testing
- Stranded palladium seed interstitial implant, 3 dimensional breast ultrasound, Computerized tomography (CT)
- Where
- Canada
- Volunteers
- 75 people
- Sponsor
- British Columbia Cancer Agency
Localized Prostate Carcinoma
Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer
This is an observational single-center trial for patients with localized prostate cancer suitable for High Dose Rate (HDR) brachytherapy as monotherapy.
- Trial name
- BrachyTRACKS (NCT06200974)
- Testing
- High dose rate prostate brachytherapy
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer
LDR vs. HDR Brachytherapy for Prostate Cancer
H17-02904 is a randomized comparison of low dose rate vs. high dose rate prostate brachytherapy for favorable and intermediate risk prostate cancer suitable for brachytherapy as monotherapy.
- Trial name
- LDR/HDRmono (NCT03426748)
- Testing
- Low dose rate prostate brachytherapy, High dose rate prostate brachytherapy
- Where
- Canada
- Volunteers
- 140 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer
Improving Quality of Life After Prostate Brachytherapy: a Comparison of HDR and LDR Brachytherapy
Optimal non surgical treatment of prostate cancer requires dose escalation which is frequently provided by adding a brachytherapy "boost" to a short course of external beam radiotherapy.
- Trial name
- BrachyQOL (NCT01936883)
- Testing
- HDR, LDR
- Where
- Canada
- Volunteers
- 195 people
- Sponsor
- British Columbia Cancer Agency
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Metastatic
177Lu-HTK03170 in mCRPC With PSMA Positive Disease
This study will determine the safe initial injected activity of the radioligand therapy 177Lu-HTK03170 for the measurement of dosimetry and initiation of treatment in subjects with PSMA-positive, metastatic castrate resistant…
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Metastatic, Castrate Resistant Prostate Cancer
- Trial name
- NCT05570994
- Testing
- 177Lu HTK03170, 68Ga-HTK03149
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- British Columbia Cancer Agency
Oligoprogression, Oligometastatic Disease
Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers
STOP-2 is a phase III multi-institutional double-blind randomized trial. 194 participants will be enrolled in this trial. Participants will be randomized in a 1:1 ratio between the Control Arm vs. the Experimental Arm.
- Conditions
- Oligoprogression, Oligometastatic Disease, OligoProgressive Metastatic Disease
- Trial name
- NCT06918951
- Testing
- Stereotactic ablative radiotherapy (SABR), Palliative radiotherapy
- Where
- Canada
- Volunteers
- 194 people
- Sponsor
- British Columbia Cancer Agency
Metastatic Cancers, Advanced Cancers
Personalized Oncogenomics (POG) Program of British Columbia
The genomic heterogeneity of cancers implies that to effectively use targeted therapies the investigators will need to assess each individual cancer and match it to a biologically relevant targeted therapy.
- Conditions
- Metastatic Cancers, Advanced Cancers, Cancers That Cannot be Treated With Curative Intent
- Trial name
- NCT02155621
- Testing
- Genome sequencing
- Where
- Canada
- Volunteers
- 5,000 people
- Sponsor
- British Columbia Cancer Agency
Breast Cancer
Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer
Advanced hormone positive (HR+), HER2 negative breast cancer continues to pose a challenge when patients have progressed on CDK4/6 inhibitor and endocrine therapy leaving limited treatment options.
- Trial name
- NCT06665178
- Testing
- Sacituzumab Govitecan
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- British Columbia Cancer Agency
Cancer, Chronic Lymphocytic Leukemia
Time Restricted Eating in Haematological Malignancies
The goal of this clinical trial is to learn if time restricted eating (TRE), a form of intermittent fasting, can impact health outcomes in patients with chronic lymphocytic leukemia (CLL).
- Trial name
- NCT06862323
- Testing
- Time-Restricted Eating
- Where
- Canada
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- British Columbia Cancer Agency
Prostatic Neoplasm, Prostatic Cancer
[68Ga]Ga-PSMA-11 PET/CT in the Assessment of High Risk and Recurrent Prostate Cancer
Prostate cancer is the third most common cause of cancer death in men. Most patients with localized prostate cancer will be cured with surgery or radiation therapy, but up to 35% of patients will have their prostate cancer…
- Trial name
- NCT04484701
- Testing
- 68Ga-PSMA-11
- Where
- Canada
- Volunteers
- 1,574 people
- Sponsor
- British Columbia Cancer Agency
Breast Cancer, Metastases
SABR PRIMER - Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors
The study is being done to determine if stereotactic ablative radiotherapy (SABR) can control tumour growth for patients with metastatic breast cancer.
- Trial name
- SABR PRIMER (NCT06937281)
- Testing
- SABR
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- British Columbia Cancer Agency
Meningioma
DOTATATE PET for Meningioma Radiation Planning
68Ga-DOTATATE-based radionuclides are a novel modality in the diagnosis and treatment of central nervous system meningioma. DOTATATE is a ligand for the SSTR (somatostatin receptor), which is expressed in meningioma but not in…
- Trial name
- DOTATATE-RT (NCT06937268)
- Testing
- DOTATATE-PET scan
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- British Columbia Cancer Agency